London, UK – 15th April 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, will present at the BioTrinity 2024 conference.

Robin Bhattacherjee, Chief Executive Officer of Actimed, will present on Tuesday 23rd April at 14:40 during Science Track 1. The presentation will focus on Actimed‘s lead compound S-pindolol benzoate as a potential new treatment for cancer cachexia, including plans to prepare for Phase 2b/3 clinical trials.

BioTrinity 2024 will be held at ETC Venues, 133 Houndsditch, London on Tuesday 23rd and Wednesday 24th April 2024. For more information on BioTrinity 2024, visit the BioTrinity homepage.